SG10201912475XA - Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy - Google Patents

Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy

Info

Publication number
SG10201912475XA
SG10201912475XA SG10201912475XA SG10201912475XA SG10201912475XA SG 10201912475X A SG10201912475X A SG 10201912475XA SG 10201912475X A SG10201912475X A SG 10201912475XA SG 10201912475X A SG10201912475X A SG 10201912475XA SG 10201912475X A SG10201912475X A SG 10201912475XA
Authority
SG
Singapore
Prior art keywords
immunotherapy
predicting
usefulness
methods
amino acid
Prior art date
Application number
SG10201912475XA
Other languages
English (en)
Inventor
Ugur Sahin
Original Assignee
Biontech Rna Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Rna Pharmaceuticals Gmbh filed Critical Biontech Rna Pharmaceuticals Gmbh
Publication of SG10201912475XA publication Critical patent/SG10201912475XA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464456—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464488—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70517—CD8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG10201912475XA 2017-06-09 2018-06-01 Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy SG10201912475XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2017/064140 WO2018224166A1 (en) 2017-06-09 2017-06-09 Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy

Publications (1)

Publication Number Publication Date
SG10201912475XA true SG10201912475XA (en) 2020-02-27

Family

ID=59227704

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201911618UA SG11201911618UA (en) 2017-06-09 2018-06-01 Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
SG10201912475XA SG10201912475XA (en) 2017-06-09 2018-06-01 Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201911618UA SG11201911618UA (en) 2017-06-09 2018-06-01 Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy

Country Status (14)

Country Link
US (1) US20200209251A1 (zh)
EP (1) EP3635408A1 (zh)
JP (2) JP7396903B2 (zh)
KR (1) KR102560750B1 (zh)
CN (1) CN110741260B (zh)
AR (1) AR112601A1 (zh)
AU (1) AU2018279117A1 (zh)
BR (1) BR112019022349A2 (zh)
CA (1) CA3066308A1 (zh)
IL (1) IL271031A (zh)
MA (1) MA49246A (zh)
SG (2) SG11201911618UA (zh)
TW (2) TW202426040A (zh)
WO (2) WO2018224166A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4046651A1 (en) * 2021-02-23 2022-08-24 baseclick GmbH Method for producing an mrna tumor vaccine
CN115620810B (zh) * 2022-12-19 2023-03-28 北京诺禾致源科技股份有限公司 基于第三代基因测序数据的外源插入信息的检测方法和装置

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE512160T1 (de) * 2005-04-26 2011-06-15 Immatics Biotechnologies Gmbh T-cell-epitope aus dem unreifen lamininrezeptorprotein (oncofoetal antigen) und deren medizinische verwendungen
NZ730355A (en) * 2011-05-24 2022-10-28 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Individualized vaccines for cancer
WO2014082729A1 (en) * 2012-11-28 2014-06-05 Biontech Ag Individualized vaccines for cancer
JP6513086B2 (ja) * 2013-07-30 2019-05-15 ビオエンテッヒ・アクチェンゲゼルシャフトＢｉｏＮＴｅｃｈ ＡＧ 癌治療法の決定のための腫瘍抗原
WO2016128060A1 (en) * 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
GB201511191D0 (en) * 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma

Also Published As

Publication number Publication date
TW202426040A (zh) 2024-07-01
CN110741260A (zh) 2020-01-31
CN110741260B (zh) 2024-03-08
CA3066308A1 (en) 2018-12-13
BR112019022349A2 (pt) 2020-05-26
US20200209251A1 (en) 2020-07-02
TW201920959A (zh) 2019-06-01
JP7396903B2 (ja) 2023-12-12
WO2018224405A1 (en) 2018-12-13
EP3635408A1 (en) 2020-04-15
AU2018279117A1 (en) 2020-01-02
WO2018224166A1 (en) 2018-12-13
RU2019139982A (ru) 2021-07-09
SG11201911618UA (en) 2020-01-30
KR102560750B1 (ko) 2023-07-27
KR20200014311A (ko) 2020-02-10
IL271031A (en) 2020-01-30
AR112601A1 (es) 2019-11-20
MA49246A (fr) 2020-04-15
JP2020523016A (ja) 2020-08-06
JP2024026224A (ja) 2024-02-28
RU2019139982A3 (zh) 2021-07-09

Similar Documents

Publication Publication Date Title
HK1255383A1 (zh) 去除生物膜的肽及抗體
IL262680A (en) Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
IL259793A (en) slc45a2 peptides for immunotherapy
IL251571B (en) Variable proteins comprising the cry1da1 amino acid sequence are activated by lepidopteran
IL268731A (en) New uses of anti-SIRPG antibodies
EP3743058A4 (en) METHODS FOR PREDICTING TUMOR RESPONSE TO IMMUNOTHERAPY
GB2552749B (en) Shaped charge system having multi-composition liner
IL253518A0 (en) You will notice proteins with a high positive charge
IL248283B (en) A method for the synthesis of cloprabine
SG10202007893TA (en) Methods of immunotherapy
IL271031A (en) Methods for predicting the utility of disease-specific amino acid changes for immunotherapy
IL284816A (en) Improved immunotherapy methods
EP3509632A4 (en) IMMUNOTHERAPY AGAINST POLYOMAVIRUS
HUE057882T2 (hu) Eljárás karbodiimidek elõállítására
GB201821205D0 (en) Immunotherapy
IL254205B (en) Reagents for the acylation of amino acids and methods for their use